The FDA has approved nearly 10 therapies for acute myeloid leukemia (AML) over the past couple of years. Because most of them target a specific biomarker, it’s critical that people diagnosed with the condition undergo genetic testing to determine whether they fall into a particular patient subgroup.
- Datapoint, Medicare and Medicaid
- Abstract, Health Plans
- Datapoint, Drug Benefits
- Abstract, Medicare and Medicaid
- People on the Move